Suppr超能文献

利用国家和国际注册系统加强上市前医疗器械监管评估。

Utilizing national and international registries to enhance pre-market medical device regulatory evaluation.

作者信息

Yue Lilly Q, Campbell Gregory, Lu Nelson, Xu Yunling, Zuckerman Bram

机构信息

a Division of Biostatistics , Center for Devices and Radiological Health, U.S. Food and Drug Administration , Silver Spring , Maryland , USA.

b Division of Cardiovascular Devices , Center for Devices and Radiological Health, U.S. Food and Drug Administration , Silver Spring , Maryland , USA.

出版信息

J Biopharm Stat. 2016;26(6):1136-1145. doi: 10.1080/10543406.2016.1226336. Epub 2016 Aug 19.

Abstract

Regulatory decisions are made based on the assessment of risk and benefit of medical devices at the time of pre-market approval and subsequently, when post-market risk-benefit balance needs reevaluation. Such assessments depend on scientific evidence obtained from pre-market studies, post-approval studies, post-market surveillance studies, patient perspective information, as well as other real world data such as national and international registries. Such registries provide real world evidence and are playing a more and more important role in enhancing the safety and effectiveness evaluation of medical devices. While these registries provide large quantities of data reflecting real world practice and can potentially reduce the cost of clinical trials, challenges arise concerning (1) data quality adequate for regulatory decision-making, (2) bias introduced at every stage and aspect of study, (3) scientific validity of study designs, and (4) reliability and interpretability of study results. This article will discuss related statistical and regulatory challenges and opportunities with examples encountered in medical device regulatory reviews.

摘要

监管决策是基于对医疗器械上市前批准时以及随后上市后风险效益平衡需要重新评估时的风险和效益评估而做出的。此类评估依赖于从上市前研究、批准后研究、上市后监测研究、患者观点信息以及其他真实世界数据(如国家和国际注册库)中获得的科学证据。此类注册库提供真实世界证据,并在加强医疗器械的安全性和有效性评估方面发挥着越来越重要的作用。虽然这些注册库提供了大量反映真实世界实践的数据,并有可能降低临床试验成本,但在以下方面出现了挑战:(1) 足以用于监管决策的数据质量;(2) 研究各个阶段和方面引入的偏差;(3) 研究设计的科学有效性;以及(4) 研究结果的可靠性和可解释性。本文将通过医疗器械监管审查中遇到的实例,讨论相关的统计和监管挑战与机遇。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验